Minimally invasive interventions using the hemostatic agent fibrinostat
This article presents the results of use of the hemostatic agent fibrinostat for treatment of bleedings of various genesis in carrying out endovascular interventions and prevention of bleedings after the biopsy of the liver. Hemostatic agent fibrinostat was used in 4 patients with locally-spread cancer of the kidney and hematuria for embolization of the renal artery, in 1 patient with intestinal bleedingfor embolization of the splenic artery. In all cases, the final hemostasis was reached. The biopsy of the liver was carried out in 122 patients with liver diseases. The patients were divided into 2 groups: the control group (90 patients) and the main group (32 patients). In patients of the main group, fibrinostat was injected into the biopsy canal for prevention of bleeding. Four (4.4%) patients of the control group had a complication on the 1st day - postoperative bleeding. Unlike the control group, in the main group, fibrinostat prevented postoperative bleeding.